BioCentury
ARTICLE | Politics & Policy

Former OND leader Jenkins joins Greenleaf

February 2, 2017 11:35 PM UTC

John Jenkins joined regulatory consultancy Greenleaf Health Inc. (Washington, D.C.) as a principal for drug and biological products. In January, Jenkins resigned as director of the Office of New Drugs at FDA’s Center for Drug Evaluation and Research.

During his 15 years directing OND, Jenkins led the transformation of the agency into the world's most efficient reviewer of new drugs. He created and managed systems that ensure FDA's compliance with PDUFA commitments, including review action goals (see BioCentury, Jan. 2)...